ELDN
EledonDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
Current thesis
Bull case assumes positive clinical signals from FB-401 and either a partnering deal or non-dilutive capital within 12 months, driving re-rating and improved liquidity.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite, 7D delta +0.2.
What can break
Bear case assumes clinical setbacks or the need for a significant dilutive financing round within 12 months that materially increases share count and compresses the price.
Momentum
89
Value
41
Sentiment
0
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $0.08 · Bull $0.16 · Bear $0.04
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-06-01 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2025-12-08 • Model: RankAlpha Sentiment AI
Investment thesisAs of 2026-06-02
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $7.80
Why
Momentum89 · Δ7d +0.2
Value41 · Δ7d +0.1
Sentiment0 · Δ7d 0.0
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
89
34% active weight
Current posture
7d trendFlat
Δ7d
+0.2
Δ21d
-5.0
Value
41
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
0
33% active weight
Current posture
7d trendFlat
Δ7d
0.0
Δ21d
0.0
Why this grade
Composite grade D. Momentum 88.7 / Value 41.1 / Sentiment 0.0
Fundamentals (TTM)As of 2026-06-01
Fundamentals (TTM)
As of 2026-06-01
Market Cap
$290.23M
Beta
0.89
Shares Out
75.03M
P/E (TTM) · Derived
-5.2
P/S (TTM)
-
P/FCF (TTM) · Derived
-4.33
Rev YoY
-
EPS YoY
+32.8%
Gross Margin
-
Op Margin
-
Net Debt
-$140.18M
Current Ratio
6.74
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology